Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case
Authors
Keywords
Experimental Autoimmune Encephalomyelitis, Tolerance Induction, Immune Disease, Oral Tolerance Induction, Clinical Trial Application
Journal
Microbial Cell Factories
Volume 13, Issue Suppl 1, Pages S11
Publisher
Springer Nature
Online
2014-08-29
DOI
10.1186/1475-2859-13-s1-s11
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy
- (2013) Sewanti Atul Limaye et al. CANCER
- Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
- (2013) K. C. Herold et al. DIABETES
- Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial
- (2013) W. Hagopian et al. DIABETES
- Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis
- (2012) Suguru Shigemori et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Epidemiology of environmental exposures and human autoimmune diseases: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop
- (2012) Frederick W. Miller et al. JOURNAL OF AUTOIMMUNITY
- Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice
- (2012) Tatiana Takiishi et al. JOURNAL OF CLINICAL INVESTIGATION
- GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus
- (2012) Johnny Ludvigsson et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes
- (2011) Kathryn Haskins et al. CURRENT OPINION IN IMMUNOLOGY
- Vaccination with IA-2 autoantigen can prevent late prediabetic nonobese diabetic mice from developing diabetes mellitus
- (2011) Yueyan Guan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Gut-Tropic T Cells That Express Integrin α4β7 and CCR9 Are Required for Induction of Oral Immune Tolerance in Mice
- (2011) Barbara Cassani et al. GASTROENTEROLOGY
- Cytokine-inducing lipoteichoic acids of the allergy-protective bacterium Lactococcus lactis G121 do not activate via Toll-like receptor 2
- (2011) K. Fischer et al. GLYCOBIOLOGY
- Oral tolerance
- (2011) Howard L. Weiner et al. IMMUNOLOGICAL REVIEWS
- Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells
- (2011) C. Penaranda et al. JOURNAL OF IMMUNOLOGY
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial
- (2011) Nicole Sherry et al. LANCET
- Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice
- (2011) Hou Jing et al. VACCINE
- Lactococcus lactis-based vaccines from laboratory bench to human use: An overview
- (2011) Mohammed Bahey-El-Din VACCINE
- An intranasal administration of Lactococcus lactis strains expressing recombinant interleukin-10 modulates acute allergic airway inflammation in a murine model
- (2010) F. A. V. Marinho et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
- (2010) B. Keymeulen et al. DIABETOLOGIA
- Clinically validated approaches to the treatment of autoimmune diseases
- (2010) Percy H Carter et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints
- (2010) Junko Nishio et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Genetics, pathogenesis and clinical interventions in type 1 diabetes
- (2010) Jeffrey A. Bluestone et al. NATURE
- Prophylaxis of experimentally induced ovomucoid allergy in neonatal pigs using Lactococcus lactis
- (2010) P. Rupa et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
- Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients
- (2009) E. Vandemeulebroucke et al. DIABETES & METABOLISM
- GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes
- (2009) C.-D. Agardh et al. DIABETOLOGIA
- Allergy Therapy by Intranasal Administration with Recombinant Lactococcus lactis Producing Bovine β-Lactoglobulin
- (2009) Naima G. Cortes-Perez et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab Dq8 Transgenic Mice
- (2009) I. L. Huibregtse et al. JOURNAL OF IMMUNOLOGY
- Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study
- (2009) Christopher C Patterson et al. LANCET
- Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
- (2009) K Vandenbroucke et al. Mucosal Immunology
- Autoimmune mechanisms in type 1 diabetes
- (2008) Mikael Knip et al. AUTOIMMUNITY REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now